Openfund

CORDIS · HTx

Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe

Code
HTx
Programme
H2020
Call
SC1-BHC-26-2018
Status
CLOSED
Period
2019-01-01 – 2024-06-30
Total cost (whole consortium)9 640 775 €
EU contribution (whole consortium)9 640 775 €
EU contribution to Bulgarian participants313 688 €

Official data · CORDIS · synced 2026-10-17 10:16 · official record

Participants

OrganisationsRoleCountryGrant
UNIVERSITEIT UTRECHTcoordinatorNL1 352 135 €
UNIVERSITY OF YORKparticipantUK984 602 €
ORGANISATION EUROPEENNE POUR LA RECHERCHE ET LE TRAITEMENT DU CANCER AISBLparticipantBE862 250 €
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCEparticipantUK839 398 €
UNIVERSITAET BERNparticipantCH749 062 €
SYNAPSE RESEARCH MANAGEMENT PARTNERS SLparticipantES726 688 €
OULUN YLIOPISTOparticipantFI726 500 €
SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAGparticipantHU679 162 €
EURORDIS - RARE DISEASES EUROPEparticipantFR625 908 €
ZORGINSTITUUT NEDERLANDparticipantNL484 450 €
UNIVERSITEIT MAASTRICHTparticipantNL384 855 €
UNIVERSIDAD POLITECNICA DE MADRIDparticipantES382 100 €
МЕДИЦИНСКИ УНИВЕРСИТЕТparticipantBG313 688 €
TANDVARDS-OCH LAKEMEDELSFORMANSVERKETparticipantSE301 852 €
KOBENHAVNS UNIVERSITETparticipantDK228 125 €
ACADEMISCH ZIEKENHUIS GRONINGENthird partyNL0 €
UNIVERSITAIR MEDISCH CENTRUM UTRECHTthird partyNL0 €

Description

HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies. Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies. HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients. Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies. Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.

Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).